Prognostic survival models for diffuse large B-cell lymphoma using statistical and machine learning approaches.
New prognostic models better predict outcomes in diffuse large B-cell lymphoma, potentially guiding treatment intensity decisions.
Although diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, existing prognostic tools, including the revised International Prognostic Index (R-IPI) and the National Comprehensive Cancer Network (NCCN-IPI),. While our models provided promising risk stratification, external validation is warranted.
What the study was
- Study design
- Not specified
- Population
- Cancer/disease patients
- Sample size
- 2769
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- NPJ precision oncology
Why it surfaced
Matched topic(s): Hematologic malignancies, Novel therapeutics: immunotherapy, CAR-T, targeted therapy. Study design: Not specified. Score 6/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.